Hearing Loss Overview
Hearing loss is the partial or complete loss of hearing in one or both ears, ranging from mild to profound. There are many causes, and it can affect anyone at any age, but it’s most common in people older than 60. Hearing loss in older adults is known medically as presbycusis.
“Hearing Loss Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hearing Loss Market.
The Hearing Loss Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Hearing Loss Pipeline Report:
Companies across the globe are diligently working toward developing novel Hearing Loss treatment therapies with a considerable amount of success over the years. Hearing Loss Key players such as – Acousia Therapeutics, Frequency Therapeutics, Acousia Therapeutics, Decibel Therapeutics, Otonomy, Inc., Pipeline Therapeutics, AudioCure Pharma GmbH, Frequency Therapeutics, Sensorion, and others, are developing therapies for the Hearing Loss treatment
Hearing Loss Emerging therapies such as – ACOU 082, FX-345, ACOU085, DB-020, OTO 413, PIPE 505, AC102, FX-322, SENS-401, and others are expected to have a significant impact on the Hearing Loss market in the coming years.
In January 2023, Sensorion announces that the first patient has been enrolled in its Phase 2a Proof of Concept clinical trial ofSENS-401 (Arazasetron) in patients suffering from Cisplatin-Induced Ototoxicity. The exploratory Phase 2a, multicenter, randomized, controlled, open-label study, NOTOXIS, aims at evaluating the efficacy of SENS-401 to prevent ototoxicity induced bycisplat in in adult patients with a neoplastic disease
In August 2022, Sensorion initiated a Phase II a, open-label, randomized and controlled study investigating repeated twice-daily administration of oral SENS-401 in adult participants with moderately severe to profound hearing loss who have already agreed to undergo cochlear implant surgery justified by their hearing impairment
Route of Administration
Hearing Loss pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Products have been categorized under various Molecule types, such as
Hearing Loss Pipeline Therapeutics Assessment
Hearing Loss Assessment by Product Type
Hearing Loss By Stage and Product Type
Hearing Loss Assessment by Route of Administration
Hearing Loss By Stage and Route of Administration
Hearing Loss Assessment by Molecule Type
Hearing Loss by Stage and Molecule Type
DelveInsight’s Hearing Loss Report covers around 35+ products under different phases of clinical development like-
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Some of the key companies in the Hearing Loss Therapeutics Market include:
Key companies developing therapies for Hearing Loss are – Decibel Therapeutics, Frequency Therapeutics, Otonomy Inc., Cochlear Ltd., MED-EL, Advanced Bionics AG, GN Hearing, Sonova Holding AG, Oticon Medical, Sivantos Group, and others.
Emerging Hearing Loss Drugs Under Different Phases of Clinical Development Include:
ACOU 082: Acousia Therapeutics
FX-345: Frequency Therapeutics
ACOU085: Acousia Therapeutics
DB-020: Decibel Therapeutics
OTO 413: Otonomy, Inc.
PIPE 505: Pipeline Therapeutics
AC102: AudioCure Pharma GmbH
FX-322: Frequency Therapeutics
Get a Free Sample PDF Report to know more about Hearing Loss Pipeline Therapeutic Assessment-
Hearing Loss Pipeline Analysis:
The Hearing Loss pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Hearing Loss with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hearing Loss Treatment.
Hearing Loss key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Hearing Loss Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hearing Loss market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Hearing Loss product details are provided in the report. Download the Hearing Loss pipeline report to learn more about the emerging Hearing Loss therapies
Hearing Loss Pipeline Market Drivers
Rapidly growing incidence of acute sensorineural hearing loss
Rise in geriatric population
Hearing Loss Pipeline Market Barriers
Challenges associated with the delivery of therapeutics for Sensorineural Hearing Loss
Poor understanding of the specific underlying pathologies
Scope of Hearing Loss Pipeline Drug Insight
Key Hearing Loss Companies: Acousia Therapeutics, Frequency Therapeutics, Acousia Therapeutics, Decibel Therapeutics, Otonomy, Inc., Pipeline Therapeutics, AudioCure Pharma GmbH, Frequency Therapeutics, Sensorion, and others
Key Hearing Loss Therapies: ACOU 082, FX-345, ACOU085, DB-020, OTO 413, PIPE 505, AC102, FX-322, SENS-401, and others
Hearing Loss Therapeutic Assessment: Hearing Loss current marketed and Hearing Loss emerging therapies
Hearing Loss Market Dynamics: Hearing Loss market drivers and Hearing Loss market barriers
Request for Sample PDF Report for Hearing Loss Pipeline Assessment and clinical trials
Table of Contents
Hearing Loss Report Introduction
Hearing Loss Executive Summary
Hearing Loss Overview
Hearing Loss- Analytical Perspective In-depth Commercial Assessment
Hearing Loss Pipeline Therapeutics
Hearing Loss Late Stage Products (Phase II/III)
Hearing Loss Mid Stage Products (Phase II)
Hearing Loss Early Stage Products (Phase I)
Hearing Loss Preclinical Stage Products
Hearing Loss Therapeutics Assessment
Hearing Loss Inactive Products
Company-University Collaborations (Licensing/Partnering) Analysis
Hearing Loss Key Companies
Hearing Loss Key Products
Hearing Loss Unmet Needs
Hearing Loss Market Drivers and Barriers
Hearing Loss Future Perspectives and Conclusion
Hearing Loss Analyst Views
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report to know more about Hearing Loss drugs and therapies
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States